Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 2:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 393 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer, Estrogen Receptor-Positive Clear all
Completed Early Phase 1 Interventional Results available

Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

NCT03132467
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Durvalumab, Tremelimumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 9, 2026, 2:20 AM EDT
Active, not recruiting Phase 2 Interventional

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

NCT05607004
View directory record Official record
Conditions
Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
Interventions
(Z)-endoxifen, goserelin
Drug
Lead sponsor
Atossa Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 9, 2026, 2:20 AM EDT
Completed Phase 2 Interventional Results available

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

NCT01560416
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, Ganetespib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
5
States / cities
Boston, Massachusetts • Concord, New Hampshire • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 9, 2026, 2:20 AM EDT
Terminated Phase 2 Interventional Results available

Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer

NCT00194792
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
exemestane, triptorelin pamoate, capecitabine, methotrexate, vinorelbine tartrate, paclitaxel, therapeutic conventional surgery, radiation therapy, laboratory biomarker analysis
Drug · Procedure · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 9, 2026, 2:20 AM EDT
Completed Phase 1 Interventional

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

NCT03554044
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
Interventions
Anastrozole, Exemestane, Fulvestrant, Letrozole, Paclitaxel, Talimogene Laherparepvec, Tamoxifen, Nab paclitaxel, Gemcitabine, Carboplatin
Drug · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 9, 2026, 2:20 AM EDT
Recruiting Phase 2 Interventional

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

NCT07340541
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Interventions
SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine, SOC, Antiandrogen
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
New Haven, Connecticut • Baltimore, Maryland • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 9, 2026, 2:20 AM EDT
Completed Phase 2 Interventional

Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer

NCT00084396
View directory record Official record
Conditions
Breast Cancer
Interventions
letrozole, conventional surgery
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Oct 9, 2026, 2:20 AM EDT
Completed Phase 2 Interventional Results available

A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)

NCT02273973
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Placebo, Taselisib
Drug · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
Santa Ana, California • Boston, Massachusetts • Basking Ridge, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 9, 2026, 2:20 AM EDT
Recruiting Phase 1Phase 2 Interventional

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

NCT06590857
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer With Bone Involvement, Bone Metastases in Subjects With Advanced Breast Cancer, ER-Positive HER2-Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Hormone-sensitive Metastatic Breast Cancer, Hormone-Sensitive Breast Cancer
Interventions
RYZ101, Standard of Care Endocrine Therapy
Drug
Lead sponsor
RayzeBio, Inc.
Industry
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
25
States / cities
Phoenix, Arizona • Irvine, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 9, 2026, 2:20 AM EDT
Completed Phase 2 Interventional Results available

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

NCT03106077
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative, Folate Receptor Alpha Positive, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Mirvetuximab Soravtansine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 9, 2026, 2:20 AM EDT
Completed Early Phase 1 Interventional

Broccoli Sprout Extract in Treating Patients With Breast Cancer

NCT01753908
View directory record Official record
Conditions
Ductal Breast Carcinoma, Ductal Breast Carcinoma In Situ, Estrogen Receptor Negative, Estrogen Receptor Positive, Invasive Breast Carcinoma, Lobular Breast Carcinoma, Postmenopausal, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Interventions
Broccoli Sprout Extract, Laboratory Biomarker Analysis, Pharmacological Study, Placebo
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Oct 9, 2026, 2:20 AM EDT
Recruiting Phase 3 Interventional

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

NCT07541079
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Giredestrant
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
2
States / cities
Fountain Valley, California • Sterling Heights, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 9, 2026, 2:20 AM EDT
Terminated Phase 1 Interventional

A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

NCT05080842
View directory record Official record
Conditions
Breast Cancer
Interventions
AC682
Drug
Lead sponsor
Accutar Biotechnology Inc
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Denver, Colorado • Orlando, Florida • Sarasota, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 9, 2026, 2:20 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of PF-06873600 in People With Cancer

NCT03519178
View directory record Official record
Conditions
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Interventions
PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 9, 2026, 2:20 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

NCT01823835
View directory record Official record
Conditions
Breast Cancer
Interventions
GDC-0810, LHRH Agonist, Palbociclib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
8
States / cities
San Diego, California • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 9, 2026, 2:20 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
ARV-471, Fulvestrant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
87
States / cities
Encinitas, California • Fountain Valley, California • Fresno, California + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 9, 2026, 2:20 AM EDT
Recruiting Phase 2 Interventional

Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery

NCT06450873
View directory record Official record
Conditions
Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
Interventions
Coriolus Versicolor Extract, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 9, 2026, 2:20 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

NCT06247995
View directory record Official record
Conditions
Breast Cancer
Interventions
[68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Capecitabine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Newport Beach, California • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 9, 2026, 2:20 AM EDT
Recruiting Phase 3 Interventional

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

NCT07647328
View directory record Official record
Conditions
ER-Positive HER2-Negative Breast Cancer
Interventions
Camizestrant, Ribociclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
12
States / cities
Duarte, California • Palo Alto, California • Marietta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 9, 2026, 2:20 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

NCT03332797
View directory record Official record
Conditions
Breast Cancer
Interventions
GDC-9545, Palbociclib, LHRH Agonist
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 9, 2026, 2:20 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer

NCT00767520
View directory record Official record
Conditions
Breast Cancer
Interventions
Exemestane + Dasatinib, Exemestane + Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Fountain Valley, California • Riverside, California • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 9, 2026, 2:20 AM EDT
Recruiting Phase 2 Interventional

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

NCT04886531
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
Interventions
Neratinib, Letrozole (L) or Anastrozole (A), Trastuzumab
Drug
Lead sponsor
Ruth O'Regan
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Rochester, New York • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 9, 2026, 2:20 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Study of Dotatate Imaging in Breast Cancer

NCT05880394
View directory record Official record
Conditions
Breast Cancer Stage IV
Interventions
Gallium-68 DOTATATE, Copper-64 DOTATATE
Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 9, 2026, 2:20 AM EDT
Completed Phase 1 Interventional

MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

NCT01344031
View directory record Official record
Conditions
Estrogen Receptor Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Akt Inhibitor MK2206, Anastrozole, Fulvestrant, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 9, 2026, 2:20 AM EDT